secwatch.observer — SEC 8-K summary
======================================

Issuer:     Alkermes plc. (ALKS)
CIK:        0001520262
Form:       8-K
Filed at:   2025-07-29T23:59:59+00:00
Accession:  0000950170-25-099382
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Alkermes Q2 revenue $390.7M, GAAP EPS $0.52; product sales grow 14% YoY
-----------------------------------------------------------------------

- Total Q2 revenues $390.7M (-2% YoY); GAAP net income $87.1M, diluted EPS $0.52.
- Proprietary net sales $307.2M (+14% YoY): LYBALVI $84.3M (+18%), ARISTADA $101.3M (+18%), VIVITROL $121.7M (+9%).
- Adjusted EBITDA $126.5M; cash & investments $1.05B at June 30, 2025.
- Company reaffirms 2025 financial expectations.
- R&D spend $77.4M (+30% YoY) on alixorexton; positive Vibrance-1 phase 2 results support global phase 3.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1520262/000095017025099382/0000950170-25-099382-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1520262/000095017025099382/alks-20250729.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-099382

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer